drugset

Drugs / V-306

Follow last change Mar 2022 re-read 3 minutes ago

V-306

Developed for: respiratory syncytial virus bronchiolitis
Investigated by: Center of Vaccinology, Ghent, Belgium (CEVAC) · Expert Clinical Services Organization, Brussels, Belgium (ECSOR) · Virometix

Trials 1

today NCT04519073 · Ph 1

202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT04519073	Sep 2020 → Mar 2022	respiratory syncytial virus bronchiolitis	Virometix	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2021-07-14	Virometix	Results Virometix Announces Publication of Key Non-Clinical Proof-of-Concept Data in Two High Quality Peer-Reviewed Journals. virometix.com ↗ The data confirm the potential of V-306 for prophylaxis against Respiratory Syncytial Virus (RSV) infection, possibly using a convenient needle-free method of vaccination.

All press releases naming this drug 4 releases

Date	Issuer	Release
2021-07-14	Virometix	Virometix Announces Publication of Key Non-Clinical Proof-of-Concept Data in Two High Quality Peer-Reviewed Journals. virometix.com ↗
2020-09-17	Virometix	Virometix Announces Completion of Initial Vaccination of the First Dose Cohort in Phase 1 Study with V-306 virometix.com ↗
2020-03-12	Virometix	Virometix announces initiation of Phase 1 clinical trial with its V-306 vaccine candidate. virometix.com ↗
2019-02-01	Virometix	Virometix announces initiation of Phase 1 clinical trial with its V-306 vaccine candidate virometix.com ↗

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	V-306	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04519073 ↗